AMUNDSENHot Line 2Lipids
Evolocumab Administration Before Percutaneous Coronary Intervention in Acute Myocardial Infarction
Evolocumab before percutaneous coronary intervention for acute myocardial infarction
Presenting authorGilles MontalescotInterventional / Structural Cardiology · Maastricht University Medical CentreGilles Montalescot is Professor of Cardiology at Pitié-Salpêtrière Hospital and Sorbonne University in Paris, France. He is an interventional cardiologist and president of the ACTION group. His research focuses on acute coronary syndromes, antiplatelet therapies, and myocardial revascularization guidelines.
Overview
ESC 2026 results pending; leaves open pre-PCI evolocumab benefit in acute MI.
Key result
Evolocumab administered before percutaneous coronary intervention for acute myocardial infarction currently has pending results from the ESC Congress 2026.
Discussion
Expert reaction lands here the moment AMUNDSEN reports.
Key Points
- Evolocumab administration prior to percutaneous coronary intervention aims to evaluate clinical outcomes during acute myocardial infarction management.
- Clinical trial investigation evaluates the timing of evolocumab before percutaneous coronary intervention for acute myocardial infarction events.
- Anticipated trial findings may highlight the clinical utility of rapid lipid-lowering therapy before percutaneous coronary intervention procedures.
Main Result
Absolute Event Rate: 0% vs 0%